

Appl. No. : 10/063,569
Filed : May 2, 2002

AMENDMENTS TO THE CLAIMS

1-3. (Canceled).

4. (Currently Amended) ~~The An isolated polypeptide of Claim 1~~ having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 64~~ (SEQ ID NO: 64);

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 64~~ (SEQ ID NO: 64), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64), lacking its associated signal peptide; or~~

~~(c)(e)~~ the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650;

wherein said isolated polypeptide is more highly expressed in normal skin and esophageal tumor than in melanoma tumor and normal esophagus, respectively, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal skin and esophageal tumor than in melanoma tumor and normal esophagus, respectively.

5. (Currently Amended) The isolated polypeptide of ~~Claim 1~~ Claim 4 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 64~~ (SEQ ID NO: 64);

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 64~~ (SEQ ID NO: 64), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64), lacking its associated signal peptide; or~~

~~(c)(e)~~ the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650;

wherein said isolated polypeptide is more highly expressed in normal skin and esophageal tumor than in melanoma tumor and normal esophagus, respectively, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal skin and esophageal tumor than in melanoma tumor and normal esophagus, respectively.

6. (Currently Amended) An isolated polypeptide comprising:
 - (a) the amino acid sequence of the polypeptide of shown in Figure 64 (SEQ ID NO: 64);
 - (b) the amino acid sequence of the polypeptide of shown in Figure 64 (SEQ ID NO: 64), lacking its associated signal peptide; or
 - ~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64);~~
 - ~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 64 (SEQ ID NO: 64), lacking its associated signal peptide; or~~
 - (c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650.
7. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of shown in Figure 64 (SEQ ID NO: 64).
8. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of shown in Figure 64 (SEQ ID NO: 64), lacking its associated signal peptide.
- 9-10. (Canceled).
11. (Original) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650.
12. (Currently Amended) A chimeric polypeptide comprising a polypeptide according to ~~Claim 1~~ Claim 4 fused to a heterologous polypeptide.
13. (Currently Amended) The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is ~~an epitope~~ a tag polypeptide or an Fc region of an immunoglobulin.
14. (New) An isolated polypeptide having at least 95% amino acid sequence identity to:

Appl. No. : 10/063,569
Filed : May 2, 2002

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 64;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 64, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650;

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 64 in skin tissue or esophagus samples.

15. (New) The isolated polypeptide of Claim 14 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 64;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 64, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203650;

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 64 in skin tissue or esophagus tissue samples.

16. (New) A chimeric polypeptide comprising a polypeptide according to Claim 14 fused to a heterologous polypeptide.

17. (New) The chimeric polypeptide of Claim 16, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

Appl. No. : **10/063,569**
Filed : **May 2, 2002**

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.